Recent Posts

• Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
• Spark Therapeutics Announces New Preclinical Data for Their Pompe Disease Gene Therapy Candidate
• Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study
• Audentes Therapeutics program update for Pompe disease
• Sarepta Therapeutics signs agreement with Lacerta Therapeutics, gaining rights to CNS-targeted Gene Therapy programs